Deep Vein Thrombosis

Clinical Trial Finder

Many patients with deep vein thrombosis are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Stent Versus Conservative Treatment in Patients With Deep Venous Obstruction

Conditions:   Deep-Venous Thrombosis;   Deep Venous Stenting;   Randomized Clinical Trial
Intervention:   Device: deep venous stenting
Sponsor:   Maastricht University Medical Center
Not yet recruiting - verified January 2017

Outcomes Study in Patients Receiving Aspirin With Mechanical Compression Devices Versus Aspirin Alone Following Knee and Hip Arthroplasty

Conditions:   DVT - Deep Vein Thrombosis;   PE - Pulmonary Thromboembolism
Interventions:   Drug: Aspirin;   Device: (Post- discharge) Mechanical Compression Device
Sponsors:   Washington University School of Medicine;   Medical Compression Systems
Not yet recruiting - verified January 2017

PREvention of VENous ThromboEmbolism Following Radical Prostatectomy

Conditions:   Prostate Cancer;   Venous Thromboembolism;   Lymphocele After Surgical Procedure;   Deep Venous Thrombosis;   Pulmonary Embolism
Intervention:   Drug: Subcutaneous Heparin
Sponsor:   Johns Hopkins University
Not yet recruiting - verified January 2017

Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus

Condition:   Left Ventricular Thrombosis
Interventions:   Drug: Apixaban 5 MG Oral Tablet [ELIQUIS];   Drug: Warfarin Sodium
Sponsors:   University of Science Malaysia;   INSTITUT JANTUNG NEGARA
Recruiting - verified January 2017

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

Condition:   Thromboembolism
Interventions:   Drug: Dabigatran etexilate;   Drug: Warfarin
Sponsor:   Boehringer Ingelheim
Recruiting - verified January 2017

Tranexamic Acid and Blood Clots in Knee Surgery

Condition:   Venous Thrombosis
Intervention:   Drug: Tranexamic Acid
Sponsor:   University of New Mexico
Recruiting - verified January 2017

Tumor-educated Platelets in Venous Thromboembolism

Conditions:   Neoplasms;   Venous Thromboembolism
Intervention:  
Sponsor:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting - verified January 2017

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer

Condition:   Venous Thrombosis and Pulmonary Embolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY 59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified January 2017

INvestigating SIGnificant Health TrendS in the Management of Superficial Vein Thrombosis

Condition:   Superficial Vein Thrombosis
Interventions:   Drug: any drug;   Procedure: any procedure/surgery;   Other: Any non-pharmacological treatment of SVT
Sponsor:   GWT-TUD GmbH
Recruiting - verified January 2017

Safety of Topical Tranexamic Acid in Total Joint Arthroplasty in High Risk Patients

Conditions:   Pulmonary Embolism;   Deep Vein Thrombosis;   Stroke;   Myocardial Infarction
Interventions:   Drug: Tranexamic Acid;   Drug: Normal saline
Sponsor:   Albert Einstein College of Medicine of Yeshiva University
Not yet recruiting - verified December 2015

D-dimer Testing Tailored to Clinical Pretest Probability in Suspected Pulmonary Embolism

Condition:   Pulmonary Embolism
Intervention:  
Sponsors:   McMaster University;   Canadian Institutes of Health Research (CIHR)
Recruiting - verified January 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified January 2017

Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial

Conditions:   Renal Cell Carcinoma;   Kidney Cancer
Interventions:   Drug: Sunitinib;   Drug: Isoquercetin;   Drug: Placebo
Sponsors:   Consorzio Oncotech;   Clinical Research Technology S.r.l.;   Quercegen Pharmaceuticals
Recruiting - verified January 2017

Study of a Novel Thrombectomy Device to Treat Acute Iliofemoral Deep Venous Thrombosis

Condition:   Venous Thrombosis
Interventions:   Device: a manual spiral thrombus broken suction device;   Procedure: catheter-directed thrombolysis;   Drug: low-molecular-weight heparin calcium;   Drug: urokinase
Sponsor:   Xuzhou Medical University
Enrolling by invitation - verified January 2017

The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study

Condition:   Venous Thromboembolism
Interventions:   Drug: Enoxaparin;   Drug: Placebo
Sponsor:   University Hospital, Brest
Recruiting - verified January 2017

Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: PEAGE

Conditions:   Elderly;   Pulmonary Embolism;   Anticoagulants
Intervention:   Other: 4 blood samples
Sponsors:   Centre Hospitalier Universitaire de Saint Etienne;   Ministry of Health, France
Recruiting - verified September 2016

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified January 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified January 2017

Personalized Medicine Decision-Making in a Virtual Clinical Setting

Conditions:   Deep Vein Thrombosis;   Blood Clots
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting - verified June 16, 2016

Cohort Study to Identify Cancer Patients at High Risk of Venous Thromboembolism

Conditions:   Cancer;   Deep Venous Thrombosis;   Pulmonary Embolism
Intervention:  
Sponsors:   Harry R. Buller;   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   VU University Medical Center;   University Medical Center Groningen;   Slotervaart Hospital;   Hôpital Louis Mourier;   Università degli Studi 'G. d'Annunzio' Chieti e Pescara;   Instituto Nacional de Cancerologia de Mexico
Completed - verified January 2017

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Conditions:   Pulmonary Embolism;   Thromboembolism;   Thrombosis;   Venous Thrombosis;   Venous Thromboembolism
Interventions:   Drug: BAY 59-7939;   Drug: BAY 59-7939;   Drug: ASA
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Completed - verified January 2017

Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism

Conditions:   Hypercortisolism;   Cushing Syndrome
Interventions:   Procedure: Adrenalectomy;   Other: Observation
Sponsors:   National Cancer Institute (NCI);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   CC-OADRIS
Recruiting - verified September 27, 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified January 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified January 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified January 2017

Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)

Condition:   Venous Thrombosis
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Completed - verified January 2017

Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication

Condition:   Venous Thrombosis
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Completed - verified January 2017

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Conditions:   Deep Vein Thrombosis;   Venous Thrombosis
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Research & Development, LLC
Completed - verified January 2017

Rosuvastatin Use to Improve the Coagulation Profile in Patients With Venous Thrombosis

Conditions:   Deep Vein Thrombosis;   Pulmonary Embolism
Intervention:   Drug: Rosuvastatin
Sponsors:   Leiden University Medical Center;   Netherlands Heart Foundation
Completed - verified January 2017

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Condition:   Deep Vein Thrombosis
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Unfractionated heparin;   Drug: Warfarin
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Completed - verified January 2017

Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Unfractionated heparin;   Drug: Warfarin
Sponsors:   Bayer;   Janssen Research & Development, LLC
Completed - verified January 2017

Dose-confirmatory Bridging Study in Total Knee Replacement

Condition:   Venous Thromboembolism
Interventions:   Drug: Rivaroxaban (BAY59-7939);   Drug: Rivaroxaban (BAY59-7939);   Drug: Rivaroxaban (BAY59-7939);   Drug: Enoxaparin
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Completed - verified January 2017

Dose-confirmatory Bridging Study in Total Hip Replacement

Condition:   Venous Thromboembolism
Interventions:   Drug: Rivaroxaban (BAY59-7939);   Drug: Rivaroxaban (BAY59-7939);   Drug: Rivaroxaban (BAY59-7939);   Drug: Enoxaparin
Sponsors:   Bayer;   Janssen Research & Development, LLC
Completed - verified January 2017

Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults

Condition:   HIV
Intervention:  
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 29, 2016

Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)

Conditions:   Recurrent Venous Thromboembolism;   Idiopathic Deep Vein Thrombosis
Interventions:   Drug: warfarin;   Drug: placebo of warfarin
Sponsor:   University Hospital, Brest
Completed - verified January 2017

Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. "PADIS-PE" Study.

Condition:   Pulmonary Embolism
Interventions:   Drug: warfarin;   Drug: placebo of warfarin
Sponsor:   University Hospital, Brest
Completed - verified January 2017

Low-Dose rtPA to Treat Blood Clots in Major Arm or Neck Veins

Condition:   Thrombosis
Intervention:   Procedure: Pulse-sprayed injection of recombinant tissue plasminogen activator (rtPA)
Sponsor:   National Institutes of Health Clinical Center (CC)
Completed - verified December 10, 2007